207 related articles for article (PubMed ID: 22824624)
1. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
[TBL] [Abstract][Full Text] [Related]
2. Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.
Szepeshazi K; Schally AV; Block NL; Halmos G; Nadji M; Szalontay L; Vidaurre I; Abi-Chaker A; Rick FG
Oncotarget; 2013 May; 4(5):751-60. PubMed ID: 23744510
[TBL] [Abstract][Full Text] [Related]
3. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
4. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
[TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
6. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Szepeshazi K; Schally AV; Halmos G
Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
8. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
[TBL] [Abstract][Full Text] [Related]
9. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
10. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
[TBL] [Abstract][Full Text] [Related]
11. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Jaszberenyi M; Schally AV; Block NL; Nadji M; Vidaurre I; Szalontay L; Rick FG
Oncotarget; 2013 Mar; 4(3):422-32. PubMed ID: 23518876
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
16. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
17. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
[TBL] [Abstract][Full Text] [Related]
18. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
[TBL] [Abstract][Full Text] [Related]
19. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
[TBL] [Abstract][Full Text] [Related]
20. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]